With an ambitious promise to unravel the biology of cellular rejuvenation programming, Altos Labs Inc. launched Jan. 19 with $3 billion in committed funding and an impressive roster of academic and industry leaders.

PARIS – Healshape SAS is preparing a $6.8 million series A round to develop a 3D bioprinted breast implant obtained from the patients' own cells. Supported by Pulsalys SAS, Lyon Saint-Etienne’s technology transfer acceleration company, this startup from Villeurbanne, France, has already benefited from more than a million dollars of French public funding and subsidies.

Cellusion Inc. recently closed a ¥1.1 billion ($9.5 million) financing, bringing its total 2021 fundraising to ¥1.7 billion. The company is preparing to enter the clinic with CL-S001, its corneal endothelial substitute cell candidate for treating corneal edema due to endothelial dysfunction, or bullous keratopathy.

Viveon Health Acquisition Corp. (VHAQ) reported a merger deal with regenerative aesthetics company Suneva Medical Inc. According to the terms of the deal, the special purpose acquisition company (SPAC), will issue 25 million shares and up to 12 million earnout shares to Suneva shareholders. The pro forma equity valuation of the companies is expected to be approximately $511 million, with the merger slated for completion in the first half of 2022.